The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; QBiotics; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Caroline Robert
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Lev V. Demidov
Honoraria - BioCad; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - BioCad; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - BioCad; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Amgen; Array BioPharma; BioCad; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Expert Testimony - BioCad; Bristol-Myers Squibb; MSD; Novartis; Roche
 
Avinash Gupta
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Bettina Ryll
Honoraria - MSD; Pfizer
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Clinigen Group; MSD; Novartis; Roche
Other Relationship - Melanoma Patient Network Europe
 
Flora Miranda
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Hiya Banerjee
Employment - Novartis
Stock and Other Ownership Interests - Bristol-Myers Squibb (I)
 
Mike R. Lau
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Michele Del Vecchio
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Sanofi
Research Funding - Bristol-Myers Squibb (Inst)